For the quarter ended June 2025, Teleflex (TFX Quick QuoteTFX - Free Report) reported revenue of $780.89 million, up 4.2% over the same period last year. EPS came in at $3.73, compared to $3.42 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $771.12 million, representing a surprise of +1.27%. The company delivered an EPS surprise of +11.01%, with the consensus EPS estimate being $3.36.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenues- Americas: $525.7 million versus $483.49 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.
• Geographic Revenues- EMEA: $166.2 million versus the eight-analyst average estimate of $162.22 million.
• Geographic Revenues- Asia: $89 million versus the eight-analyst average estimate of $96.61 million.
• Net Revenues- Interventional: $170 million versus $153.83 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +20.4% change.
• Net Revenues- Interventional Urology: $76.4 million compared to the $76.09 million average estimate based on 12 analysts. The reported number represents a change of -8.1% year over year.
• Revenues- OEM (Original Equipment Manufacturer and Development Services): $78.7 million versus the 12-analyst average estimate of $76.34 million. The reported number represents a year-over-year change of -11.4%.
• Net Revenues- Vascular Access: $185.5 million versus the 12-analyst average estimate of $189.93 million. The reported number represents a year-over-year change of +2.4%.
• Net Revenues- Anesthesia: $96.4 million versus $103.9 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a -6% change.
• Net Revenues- Other: $59.9 million versus the 12-analyst average estimate of $56.23 million. The reported number represents a year-over-year change of +43.7%.
• Net Revenues- Surgical: $114 million versus the 12-analyst average estimate of $114.77 million. The reported number represents a year-over-year change of +2.4%.

View all Key Company Metrics for Teleflex here>>>

Shares of Teleflex have returned -6.3% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.